B
THRD

Bailard’s Third Harmonic Bio THRD Stock Holding History

Bailard’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,400
Closed -$42.8K – 787
2023
Q1 		$42.8K Buy
+10,400
New +$44.2K ﹤0.01% 700

Other funds holding THRD

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bailard's THRD Position: Q2 2023 in Review

Bailard sold out of Third Harmonic Bio (THRD) in Q2 2023, closing a stake of 10,400 shares — an estimated $42.8K sold.

Bailard first reported a position in THRD in Q1 2023 and held it in 1 quarter. The position peaked at $42.8K in Q1 2023. 48 funds tracked by Wall St. Rank hold THRD as of Q2 2023.

  • Bailard reported no remaining Third Harmonic Bio position as of Q2 2023 after selling out during the quarter.
  • Bailard sold 10,400 Third Harmonic Bio shares in Q2 2023, an estimated $42.8K.
  • Bailard first reported a position in Third Harmonic Bio in Q1 2023 and held it in 1 quarter.
  • Bailard's Third Harmonic Bio position peaked at $42.8K in Q1 2023.
  • 48 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q2 2023.

Based on Bailard's 13F filing for Q2 2023, filed 20 Jul 2023.